C. Mendiola

847 total citations
28 papers, 388 citations indexed

About

C. Mendiola is a scholar working on Oncology, Reproductive Medicine and Surgery. According to data from OpenAlex, C. Mendiola has authored 28 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Reproductive Medicine and 7 papers in Surgery. Recurrent topics in C. Mendiola's work include Ovarian cancer diagnosis and treatment (11 papers), Cancer Treatment and Pharmacology (10 papers) and Breast Cancer Treatment Studies (5 papers). C. Mendiola is often cited by papers focused on Ovarian cancer diagnosis and treatment (11 papers), Cancer Treatment and Pharmacology (10 papers) and Breast Cancer Treatment Studies (5 papers). C. Mendiola collaborates with scholars based in Spain, Italy and France. C. Mendiola's co-authors include H. Cortés-Funes, Eva Ciruelos, J. Lindtner, Alan S. Coates, S. Pecorelli, Jan B. Vermorken, Bernard Chevalier, Fernando Rivera, Beat Thürlimann and Marco Colleoni and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

C. Mendiola

28 papers receiving 374 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Mendiola Spain 11 185 97 93 86 71 28 388
Seyran Yiğit Türkiye 14 181 1.0× 74 0.8× 95 1.0× 76 0.9× 84 1.2× 43 433
Jean Paul Guastalla France 12 206 1.1× 81 0.8× 145 1.6× 81 0.9× 58 0.8× 34 436
C O'Flaherty United States 6 187 1.0× 117 1.2× 149 1.6× 127 1.5× 90 1.3× 8 430
P. Athanassiades Greece 12 139 0.8× 85 0.9× 61 0.7× 179 2.1× 93 1.3× 47 470
W. P. McGuire United States 8 117 0.6× 102 1.1× 123 1.3× 95 1.1× 47 0.7× 21 334
B.J. Monk United States 11 135 0.7× 104 1.1× 191 2.1× 71 0.8× 72 1.0× 57 367
Karen Theilade Denmark 6 160 0.9× 146 1.5× 201 2.2× 77 0.9× 54 0.8× 7 388
Daniel Patterson United Kingdom 10 94 0.5× 135 1.4× 120 1.3× 121 1.4× 63 0.9× 17 644
G. C. Torre Italy 5 69 0.4× 78 0.8× 153 1.6× 104 1.2× 44 0.6× 8 325
Gloria Mittica Italy 12 304 1.6× 51 0.5× 156 1.7× 137 1.6× 94 1.3× 19 519

Countries citing papers authored by C. Mendiola

Since Specialization
Citations

This map shows the geographic impact of C. Mendiola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Mendiola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Mendiola more than expected).

Fields of papers citing papers by C. Mendiola

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Mendiola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Mendiola. The network helps show where C. Mendiola may publish in the future.

Co-authorship network of co-authors of C. Mendiola

This figure shows the co-authorship network connecting the top 25 collaborators of C. Mendiola. A scholar is included among the top collaborators of C. Mendiola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Mendiola. C. Mendiola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blancas, Isabel, M. Fontanillas, J. Lao, et al.. (2017). Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. Clinical & Translational Oncology. 20(7). 862–869. 4 indexed citations
2.
González-Martı́n, Antonio, Andrés Redondo, M. Jurado, et al.. (2013). GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clinical & Translational Oncology. 15(7). 509–525. 9 indexed citations
3.
Oskay-Özcelik, Gülten, Maren Keller, Sandro Pignata, et al.. (2013). Expression III: What do primary and recurrent ovarian cancer (OC) patients expect from their doctors and therapy management? Results of a survey in eight European countries with 1,743 patients (NOGGO/ENGOT-OV9 study).. Journal of Clinical Oncology. 31(15_suppl). 5569–5569. 3 indexed citations
4.
Manso, Luís, Natalia Valdiviezo, Juan Manuel Sepúlveda-Sánchez, et al.. (2012). Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. Clinical & Translational Oncology. 15(6). 467–471. 10 indexed citations
5.
Vega, Estela, Eva Ciruelos, Natalia Valdiviezo, et al.. (2011). Lobular carcinoma of the breast: outcome of 205 patients. Breast Cancer Research. 13(S2). 1 indexed citations
6.
Mendiola, C., Natalia Valdiviezo, Eduardo A. Vega, et al.. (2011). Altretamine for recurrent ovarian cancer or as maintenance after response to second-line therapy.. Journal of Clinical Oncology. 29(15_suppl). e15589–e15589. 4 indexed citations
7.
Ciruelos, Eva, Javier Cortés, H. Cortés-Funes, et al.. (2009). Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). Annals of Oncology. 21(7). 1442–1447. 10 indexed citations
8.
Keshaviah, Aparna, Silvia Dellapasqua, Nicole Rotmensz, et al.. (2007). CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Annals of Oncology. 18(4). 701–708. 80 indexed citations
9.
Poveda, Andrés, Ramón Salazar, C. Mendiola, et al.. (2007). Update in the management of ovarian and cervical carcinoma. Clinical & Translational Oncology. 9(7). 443–451. 15 indexed citations
10.
11.
12.
Perez‐Gracia, José Luis, Rámón Colomer, Ana Ruiz‐Casado, et al.. (2001). High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. Bone Marrow Transplantation. 27(2). 117–123. 4 indexed citations
13.
Hirte, Hal, Ignace Vergote, Gavin Stuart, et al.. (2001). An international multicentre Phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/Paclitaxel + Platinum containing chemotherapy (CT). 20. 15 indexed citations
14.
Lhommé, C., Jan B. Vermorken, E. Mickiewicz, et al.. (2000). Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. European Journal of Cancer. 36(2). 194–199. 41 indexed citations
15.
16.
Barnadas, Agustí, C. Mendiola, Antonio Casado, et al.. (1997). Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study. European Journal of Cancer. 33(2). 312–315. 8 indexed citations
17.
Hitt, Ricardo, et al.. (1995). A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.. PubMed. 22(6 Suppl 15). 50–4. 5 indexed citations
18.
Mayordomo, José, Luis Paz‐Ares, Fernando Rivera, et al.. (1994). Ovarian and extragonadal malignant germ-cell tumors in females: A single-institution experience with 43 patients. Annals of Oncology. 5(3). 225–231. 43 indexed citations
19.
Paz‐Ares, Luis, et al.. (1993). CMV front-line chemotherapy in transitional bladder carcinoma. Annals of Oncology. 4(2). 147–150. 9 indexed citations
20.
Méndez, Miguel, et al.. (1982). Treatment of small cell lung cancer with a combination of VP16-213 and cyclophosphamide with cisplatin or radiotherapy. Cancer Chemotherapy and Pharmacology. 7(2-3). 181–6. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seyran Yiğit Breakdown of academic impact, for papers by Jean Paul Guastalla Breakdown of academic impact, for papers by C O'Flaherty Breakdown of academic impact, for papers by P. Athanassiades Breakdown of academic impact, for papers by W. P. McGuire Breakdown of academic impact, for papers by B.J. Monk Breakdown of academic impact, for papers by Karen Theilade Breakdown of academic impact, for papers by Daniel Patterson Breakdown of academic impact, for papers by G. C. Torre Breakdown of academic impact, for papers by Gloria Mittica
Rankless by CCL
2026